<DOC>
	<DOCNO>NCT00815139</DOCNO>
	<brief_summary>Neointimal coverage stent strut important prevent stent thrombosis . But , data duration complete formation neointima om zotarolimus elute stent ( ZES ) . Previously investigational observational data 9 month show stent strut cover neointima . Therefore , investigator investigate evaluation neointimal coverage 3 month ZES implantation use novel OCT system , powerful intravascular imaging system high resolution power .</brief_summary>
	<brief_title>Evaluation Zotarolimus Eluting Stent 3 Months Using Optical Coherence Tomography</brief_title>
	<detailed_description>Stent thrombosis current main issue introduction drug-eluting stent theoretically dual antiplatelet therapy continue prevent stent thrombosis complete reendothelization . Currently , AHA/ACC guideline recommend dual antiplatelet continue least 3 month Sirolimus elute stent ( SES ) 6 month paclitaxel elute stent ( PES ) , possible , suggest use 12 month . Zotarolimus ( EndeavorÂ® ) elute stent ( ZES ) recently introduce focus reduce concern safety biocompatible polymer rapid drug elution . ENDEAVOR II trial show 0.5 per cent rate stent thrombosis 30 day - late thrombosis beyond 30 day late stent malapposition . In long term follow data Endeavor stent , two-year clinical result ENDEAVOR I impressive , low TVF MACE rate ( 2 % 3 % respectively ) absence report thromboses day 14 . These result speak , especially lack stent thrombosis 14 day , reflect well performance safety ZES . But , guideline duration dual antiplatelet therapy ZES although short duration dual antiplatelet therapy could safe compare previous drug-eluting stent . Also , data long duration might take completion reendothelialization ZES implantation living patient . The powerful histological predictor stent thrombosis endothelial coverage . The best morphometric predictor LST ratio uncover total stent strut . Because presence endothelization available vivo situation endothelialization report associated neointimal coverage stent , detection neointima stent implantation could main issue predict stent thrombosis . Recent data SES use optical coherence tomography ( OCT ) report neointimal coverage SES 3-month follow-up incomplete . The rate expose strut expose strut malapposition 15 % 6 % , respectively . These frequent patient acute coronary syndrome ( ACS ) non-ACS ( 18 % vs 13 % , p &lt; 0.0001 ; 8 % vs 5 % , p &lt; 0.005 , respectively ) . Although neointimal coverage could completely early period ZES implantation , data finding . Therefore , investigate evaluation neointimal coverage 3 month ZES implantation use novel OCT system , powerful intravascular imaging system high resolution power . This study may provide adequate information safety discontinuation dual antiplatelet therapy patient clinical situation .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Significant coronary de novo lesion ( &gt; 70 % quantitative angiographic analysis ) Patients stable acute coronary syndrome consider coronary revascularization . Nonemergent condition Reference vessel diameter 2.75 4.0 mm operator assessment The criterion exclusion contraindication antiplatelet agent ST elevation MI require primary PCI Proximal lesion within 15 mm ostium Prior insertion DES vessel Creatinine level 2.0mg/dL ESRD Severe hepatic dysfunction ( 3 time normal reference value ) Pregnant woman woman potential childbearing Life expectancy less 1 year Complex lesion morphology ( aortoostial , bifurcation &gt; 2.0 mm side branch , unprotected Left main , thrombus , severe calcification , chronic total occlusion ) Target lesion vein graft lesion Reference vessel &lt; 2.5 mm &gt; 4.0 mm diameter visual estimation Long lesion require two stent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Coronary artery disease , stent</keyword>
</DOC>